DBVT
DBV Technologies
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
DBVT Profile
Dbv Technologies S.A.
A developer of therapeutics based on epicutaneous immunotherapy to treat severe food allergies
Biological Technology
03/29/2002
10/22/2014
NASDAQ Stock Exchange
109
12-31
Depository Receipts (Ordinary Shares)
107 Av. de la République, 92320 Chatillon
--
DBV Technologies S.A. The company was incorporated under the laws of the French Republic on March 29, 2002. The company is a clinical stage specialty biopharmaceutical company focused on transforming the field of immunotherapy by developing a new technology platform called Viaskin. The company's treatment is based on epidermal immunotherapy, or EPIT, its proprietary method of using Viaskin to deliver bioactive compounds to the immune system through intact skin.